New consortium paves the way for improved treatment of hypertension
Netherlands-based Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals of Switzerland, Erasmus Medical Centre of Rotterdam, Netherlands and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Netherlands-based Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals of Switzerland, Erasmus Medical Centre of Rotterdam, Netherlands and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.
Based on novel action mechanisms, new drugs may be discovered with the potential to prevent vascular complications in patients with hypertension.
The three-year collaboration involves Euro 3.4m, nine new research jobs, unique materials and knowledge exchange.
"Our project studies the consequences of blocking the biological pathways in cells and organs that lead to hypertension. As such, the project will pave the way towards finding new ways to treat hypertension and its associated vascular complications," said Jan Danser, professor of Pharmacology at Erasmus.
The project will also focus on finding new modalities for the treatment of fibrosis and pulmonary hypertension, especially in children.